Translate Bio Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Translate Bio stock.
View analyst ratings for Translate Bio or view top-rated stocks.

Wall Street analysts have given Translate Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Translate Bio.

Translate Bio, Inc. (NASDAQ:TBIO) issued its quarterly earnings results on Thursday, November, 5th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The company had revenue of $66.45 million for the quarter, compared to the consensus estimate of $58.97 million. Translate Bio had a negative trailing twelve-month return on equity of 13.81% and a negative net margin of 7.69%.
View Translate Bio's earnings history.

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TBIO stock has increased by 150.3% and is now trading at $18.60.
View which stocks have been most impacted by COVID-19.

11 analysts have issued 12 month price targets for Translate Bio's stock. Their forecasts range from $19.00 to $40.00. On average, they anticipate Translate Bio's stock price to reach $25.80 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price.
View analysts' price targets for Translate Bio or view top-rated stocks among Wall Street analysts.

13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Translate Bio include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Kodiak Sciences (KOD), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), NanoString Technologies (NSTG), Vericel (VCEL), Bavarian Nordic A/S (BVNRY) and Revolution Medicines (RVMD).
View all of TBIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Translate Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.59%), RTW Investments LP (5.82%), Federated Hermes Inc. (4.92%), Price T Rowe Associates Inc. MD (2.40%), Goldman Sachs Group Inc. (2.12%) and Geode Capital Management LLC (1.54%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire and Jean Francois Formela.
View institutional ownership trends for Translate Bio.

TBIO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Barclays PLC, Acadian Asset Management LLC, Millennium Management LLC, Credit Suisse AG, Cubist Systematic Strategies LLC, Northern Trust Corp, and Allianz Asset Management GmbH. Company insiders that have sold Translate Bio company stock in the last year include Human Genetic Therapies Shire, and Jean Francois Formela.
View insider buying and selling activity for Translate Bio or view top insider-selling stocks.

TBIO stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Camber Capital Management LP, Federated Hermes Inc., Goldman Sachs Group Inc., EcoR1 Capital LLC, JPMorgan Chase & Co., BlackRock Inc., and Morgan Stanley.
View insider buying and selling activity for Translate Bio or or view top insider-buying stocks.

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TBIO stock can currently be purchased for approximately $18.60.

Translate Bio has a market capitalization of $1.40 billion and generates $138.81 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

Translate Bio employs 122 workers across the globe.

The official website for Translate Bio is www.translate.bio.

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.